Bristol Myers Squibb NDA for Mezigdomide Accepted by FDA
PRINCETON, New Jersey, July 13, 2026 Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
PRINCETON, New Jersey, July 13, 2026 Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration...
SANTA CLARA, California, USA, July 8, 2026 Agilent Technologies has expanded its Altura High-Performance Liquid Chromatography (HPLC) portfolio with...
BOSTON, Massachusetts, USA, July 9, 2026 Mindbeam Research has unveiled a significant advance in AI-driven drug discovery, demonstrating how...
HONG KONG, China, July 12, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and...
